C4 Therapeutics (CCCC) Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CCCC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CCCC, but not buy additional shares or sell existing shares.
View CCCC analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 1 year price targets for C4 Therapeutics' stock. Their CCCC share price forecasts range from $5.00 to $25.00. On average, they anticipate the company's share price to reach $9.86 in the next year. This suggests a possible upside of 193.4% from the stock's current price.
View analysts price targets for CCCC or view top-rated stocks among Wall Street analysts.

C4 Therapeutics' stock was trading at $5.90 at the beginning of the year. Since then, CCCC shares have decreased by 43.1% and is now trading at $3.36.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CCCC earnings forecast.

C4 Therapeutics, Inc. (NASDAQ:CCCC) released its earnings results on Wednesday, November, 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.06. The firm had revenue of $8.50 million for the quarter, compared to the consensus estimate of $7.28 million. C4 Therapeutics had a negative trailing twelve-month return on equity of 43.26% and a negative net margin of 482.83%.

ETFs with the largest weight of C4 Therapeutics (NASDAQ:CCCC) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).Harbor Disruptive Innovation ETF (INNO).

(CCCC) raised $150 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO.

C4 Therapeutics trades on the NASDAQ under the ticker symbol "CCCC."

C4 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (13.01%), Wasatch Advisors LP (11.65%), BlackRock Inc. (7.53%), Price T Rowe Associates Inc. MD (5.86%), Geode Capital Management LLC (1.71%) and State Street Corp (1.58%). Insiders that own company stock include Adam Crystal, Andrew Hirsch, Elena Prokupets, Jolie Siegel, Malcolm Salter, Marc A Cohen, Stewart Fisher, Utpal Koppikar and William Mckee.
View institutional ownership trends.

Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CCCC stock can currently be purchased for approximately $3.36.

C4 Therapeutics (NASDAQ:CCCC) has a market capitalization of $164.84 million and generates $31.10 million in revenue each year. The company earns $-128,180,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis.

The company employs 121 workers across the globe.

The official website for the company is www.c4therapeutics.com. The company can be reached via phone at 617-231-0700 or via email at jane.urheim@sternir.com.